Research map: Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model

Back to the article

Papers in this map

  1. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · Michael I. Love · 2014 · 104531 citations · Cited by this paper
  2. Roux-en-Y gastric bypass alters microbial circadian rhythms with links to metabolic improvement · 2026 · Related
  3. STAR: ultrafast universal RNA-seq aligner · Alexander Yu. Dobin · 2012 · 58150 citations · Cited by this paper
  4. Inhibiting VTCN1 overcomes immunosuppression in colorectal cancer to activate T cells via galectin-3 · 2026 · Related
  5. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† · David Erwin Kleiner · 2005 · 10909 citations · Cited by this paper
  6. Intestinal permeability responses to maximal and submaximal exercise in individuals with normal-weight obesity: an exploratory study · 2026 · Related
  7. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes · Steven P. Marso · 2016 · 6910 citations · Cited by this paper
  8. circRET-mediated regulation of RET influences enteric neural crest cell development in Hirschsprung disease · 2026 · Related
  9. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  10. Dissecting neuromuscular transmission in the gastrointestinal tract: from single-cell RNA analysis to function and pharmacology · 2026 · Related
  11. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review · Zobair M. Younossi · 2023 · 3310 citations · Cited by this paper
  12. Fibroblast-specific Gpx4 deletion exacerbates IBD via lipid peroxidation · 2026 · Related
  13. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · A. Michael Lincoff · 2023 · 3058 citations · Cited by this paper
  14. Measuring autonomic influence on gastrointestinal contractility: development and preliminary validation of novel capsule-based indices · 2026 · Related
  15. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3032 citations · Cited by this paper
  16. Epithelial fucosylation regulates intestinal stem cell differentiation · 2026 · Related
  17. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease · Paul G. Angulo · 2015 · 3025 citations · Cited by this paper
  18. Gastrointestinal Motility Effects of GLP-1 Receptor Agonists · 2025 · Related
  19. Prediabetes: a high-risk state for diabetes development · Ádám Gyula Tabák · 2012 · 3024 citations · Cited by this paper
  20. Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models · 2026 · Related
  21. Mechanisms of hepatic stellate cell activation · Takuma Tsuchida · 2017 · 2966 citations · Cited by this paper
  22. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis · Philip Noel Newsome · 2020 · 2009 citations · Cited by this paper
  23. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis · Stephen A. Harrison · 2024 · 1982 citations · Cited by this paper
  24. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  25. From NASH to HCC: current concepts and future challenges · Quentin Mark Anstee · 2019 · 1432 citations · Cited by this paper
  26. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome · Hannele Yki‐Järvinen · 2014 · 1293 citations · Cited by this paper
  27. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease · Arun Jayant Sanyal · 2021 · 1134 citations · Cited by this paper
  28. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis · Arun J. Sanyal · 2025 · 985 citations · Cited by this paper
  29. The Discovery and Development of Liraglutide and Semaglutide · Lotte Bjerre Knudsen · 2019 · 966 citations · Cited by this paper
  30. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis · Rohit Seth Loomba · 2024 · 942 citations · Cited by this paper
  31. Epidemiology of metabolic dysfunction-associated steatotic liver disease · Zobair M. Younossi · 2024 · 876 citations · Cited by this paper
  32. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody · Charles Pyke · 2014 · 870 citations · Cited by this paper
  33. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH · Sven Francque · 2021 · 779 citations · Cited by this paper
  34. Semaglutide lowers body weight in rodents via distributed neural pathways · Sanaz Gabery · 2020 · 720 citations · Cited by this paper
  35. Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Regulate Overlapping but Distinct Sets of Genes Involved in Xenobiotic Detoxification · Jodi M. Maglich · 2002 · 656 citations · Cited by this paper
  36. Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology · Wen Liang · 2014 · 618 citations · Cited by this paper
  37. The regulation of inflammation by galectin‐3 · Neil Cowan Henderson · 2009 · 529 citations · Cited by this paper
  38. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways · Günaj Rakipovski · 2018 · 520 citations · Cited by this paper
  39. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis · Arun J. Sanyal · 2024 · 500 citations · Cited by this paper

Source: OpenAlex (CC0)